在慢性乙型肝炎患者中,基于指南的监测遵守率较低:混合定量和定性研究
Cui-Ling Huang1, Cheng-Dian Lan1, Ying Yu2
1Department of General Practice, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361006, China.
Journal of infection in developing countries
|January 13, 2026
概括
在中国,对慢性乙型肝炎 (CHB) 进行基于指导方针的监测的遵守率不够理想,只有25.6%的患者符合建议. 关键的障碍包括教育不足,遗忘和成本问题.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 公共卫生 公共卫生
- 临床医学 临床医学
背景情况:
- 慢性乙型肝炎 (CHB) 管理需要遵守基于指南的监测 (GBM).
- 在中国的CHB患者群体中,GBM的坚持是研究不足的.
- 患者报告的GBM障碍尚未得到充分了解.
研究的目的:
- 评估中国CHB患者对GBM的坚持率.
- 确定与GBM坚持相关的因素.
- 探索患者报告的对GBM的障碍.
主要方法:
- 一项混合方法的研究在中国福丹大学中山医院进行.
- 来自402名CHB门诊患者 (2018年1月至2018年12月) 的定量数据包括电子医疗记录.
- 通过半结构面试收集定性数据,并根据主题进行分析.
主要成果:
- 只有25.6%的CHB患者表现出良好的遵守GBM.
- 坚持与抗病毒治疗和初始肝脏成像相关.
- 障碍包括不充分的健康教育,遗忘,成本和复杂的程序.
结论:
- 对于中国的CHB患者来说,遵守GBM是不理想的.
- 干预措施应包括技术,有针对性的教育和初级保健整合.
- 改善GBM的遵守对于有效的CHB管理至关重要.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
211
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
210
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
210
Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
Chronic Pancreatitis II: Collaborative Care
311
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
311
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
249
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249


